focus -WSS

focus

author：focus 2025-09-29 20:17:23 - browse：5

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Measles policy set amid Florida outbreak alarms vaccine proponents

WSS

Bernie Sanders gets little from pharma CEOs on drug prices

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Report cites 'urgent' need to recruit more diverse clinical trial participants

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

explore

focus

explore

Cancer drug shortages should be causing more outrage

Medicare Advantage enrollment hits roughly 33.4 million

State Dept. review finds Biden bears some blame for Afghanistan failures

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Artificial intelligence use in health care faces greater scrutiny in 2024

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Amylyx, Aurinia, and IQVIA

In age of alternative facts, a scholarly course on calling out crap

AMAs digital advisors table RPM coding reform proposal, again

hotspot

Congress might make insulin pumps more accessible to the blind

Report cites 'urgent' need to recruit more diverse clinical trial participants

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Hospitals are piloting generative AI tools as regulators play catch

WATCH: Why do our ears pop?

Latigo launches with $135 million for Vertex

hotspot

focus

Wikipedia

Wikipedia